Streetbeat News

Analyst Ratings

DOC

Over the past 3 months, 6 analysts have published their opinion on Physicians Realty Trust (NYSE:DOC) stock, with an average 12-month price target of $15.42, a 16.65% decrease from the previous average price target of $18.50.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:05 pm

AKBA

Akebia Therapeutics (NASDAQ:AKBA) has received 5 indifferent analyst ratings in the last quarter, with an average 12-month price target of $1.7, a high of $2.00, and a low of $1.25. The average price target has increased by 36.0% over the past month.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:05 pm

ZS

In the last quarter, Zscaler (NASDAQ:ZS) received 14 bullish and 2 indifferent analyst ratings. The average 12-month price target for Zscaler is $168.69, with a high of $225.00 and a low of $120.00. The average price target has increased by 2.24% over the past month.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:04 pm

OI

In the last quarter, O-I Glass (NYSE:OI) received 1 bullish and 5 somewhat bullish ratings from analysts, with an average price target of $31.83, implying an upside compared to the current price of $21.94. The average price target has increased by 12.87% over the past month.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:03 pm

DECK

Wedbush maintains its Outperform rating for Deckers Outdoor (NYSE:DECK) and raises its price target from $485.00 to $505.00. Shares of Deckers Outdoor are trading up 3.09% over the last 24 hours, at $463.89 per share.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:03 pm

APLD

Northland Capital Markets maintains its Outperform rating for Applied Digital (NASDAQ:APLD) and raises its price target from $5.00 to $11.00. Shares of Applied Digital are currently trading down 8.06% at $8.15 per share.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:03 pm

RCUS

Citigroup has maintained its Buy rating for Arcus Biosciences (NYSE:RCUS) and increased its price target from $40.00 to $41.00. Shares of Arcus Biosciences are trading up 24.06% over the last 24 hours, at $21.71 per share.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:02 pm

CGEN

Over the past 3 months, 4 analysts have published their opinion on Compugen (NASDAQ:CGEN) stock, with 2 bullish and 2 somewhat bullish ratings. The average 12-month price target for CGEN is $10.25, with a high of $13.00 and a low of $7.00. The average price target has increased by 28.12% over the past month.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:02 pm

BTAI

Goldman Sachs has maintained its Neutral rating for BioXcel Therapeutics (NASDAQ:BTAI) and lowered its price target from $28.00 to $25.00. Shares of BTAI are trading down 4.76% at $18.40 per share.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:01 pm

KOF

In the last quarter, Coca-Cola Femsa SAB de (NYSE:KOF) received one somewhat bullish rating and three indifferent ratings from analysts. The average 12-month price target for the stock is $87.05, with a high of $91.00 and a low of $85.10. The average price target has increased by 13.13% over the past month.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 5:00 pm